Table 1.
Clinical characteristics of the PD patients included in the study. Pt = patient, S = sex, A = age at the moment of the experiment, y = years, PD = Parkinson’s disease, M = male, F = female, LEDD = levodopa equivalent daily dose, L = left, R = right, C = case (used for monopolar stimulation).
| Pt | S | A (y) | Time since PD start (y) | DBS use (y) | Most affected side | Tremora | Medication | Clinical setting | Experimental setting Contacts used Parameters | Freq used for filtering (±3Hz) | OFF Beta peak (Hz)b | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contacts used | Parameters | Contacts used | Parameters | ||||||||||
| PD01c | M | 58 | 24 | 9 | Left | Levodopa, pramipexoleamantadine 1738 mg LEDD | L: 3/2+ R: 10/C+ |
2.9V 60μs 185Hz 0.8V 60μs 185Hz |
L: 2/C+ R: 10/C+ |
1.8V 60μs 130Hz 1.8V 60μs 130Hz |
15 | L: 15 R: 15 |
|
| PD02 | M | 47 | 16 | 12 | Right | No | Levodopa pramipexole 1538 mg LEDD | L: 3/2+ R: 11/C+ |
3.5V 60μs 135Hz 2.2V 60μs 135Hz |
L: 2/C+ R: 10/C+ | 2V 60μs 130Hz 2.2V 60μs 130Hz |
15 | L: 15 R: 13 |
| PD03 | M | 46 | 8 | 5 | Left | No | Levodopa duodopa 1582 mg LEDD | L: 1/2+ R: 11/10+ |
2.2V 90μs 180Hz 1.5V 90μs 180Hz |
L: 2/C+ R: 10/C+ |
1.86V 60μs 130Hz 1.86V 60μs 130Hz |
20 | L: 21 R: 21 |
| PD04 | F | 49 | 9 | 6 | Left | Yes | Levodopa rotigotine 1558 mg LEDD | L: 1/2+ R: 9/10+ |
2.8V 60μs 180Hz 1.2V 60μs 180Hz |
L: 1-/C+ R: 9/C+ |
2.8V 60μs 130Hz 1.2V 60μs 130Hz |
17 | L: 17 R: 19 |
| PD05 | M | 67 | 10 | 5 | Left | Yes | Levodopa 1500 mg LEDD | L: 2/C+ R: 11/C+ |
1.7V 60μs 180Hz 2.2V 60μs 180Hz |
L: 2/C+ R: 10/C+ |
1V 60μs 130Hz 1.3V 60μs 130Hz |
20 | L: 22 R: 21 |
| PD06d | F | 64 | 23 | 9 | Left | No | Duodopa amantadine 1759 mg LEDD | L: 2/3+ | 3V 60μs 130Hz | L: 1/C+ | 2.54V 60μs 130Hz |
22 | L:21 |
| PD07e | M | 59 | 19 | 9 | Right | Yes | Duodopa 2540 mg LEDD | L: 0/1 + R: 9/C+ |
2V 60μs 1.85Hz | L: 1/C+ | 2V 60μs 130Hz 2V 60μs 130Hz |
23 | L: 21 R: 21 |
| PD08 | M | 54 | 7 | 3 | Right | Levodopa pramipexole 725 mg LEDD | L: 0/-1/-2/3+ R: 9/10+ |
4.5V 90μs 190Hz 0.6V 60μs 190Hz |
L: 1/C+ R: 10/C+ |
2.5V 60μs 130Hz 1.5V 60μs 130Hz |
15 | L: 16 R: 16 |
|
| PD09 | M | 66 | 32 | 8 | Left | No | Levodopa, pramipexole amantadine 1125 mg LEDD | L: 1/2+ R: 10/11 + |
4.5V 90μs 135Hz 4.8V 90μs 135Hz |
L: 1/C+ R: 9/C+ |
2.05V 60μs 130Hz 2.05V 60μs 130Hz |
18 | L: 16 R: 15 |
| PD10 | M | 48 | 12 | 4 | Left | Yes | Levodopa, pramipexole amantadine 1081 mg LEDD | L: 1/C+ R: 9/C+ |
3.2V 120μs 130Hz 2.4V 120μs 130Hz |
L: 1/C+ R: 9/C+ |
3.2V 60μs 130Hz 2.4V 60μs 130Hz |
29 | L: 29 R: 27 |
| PD11 | M | 81 | 15 | 6 | Left | No | Levodopa, pramipexole amantadine 900 mg LEDD | L: 1/2+ R: 10/9+ |
2.1V 60μs 135Hz 2.5V 60μs 135Hz |
L: 1/C+ R: 10/C+ |
2.5V 60μs 130Hz 2.5V 60μs 130Hz |
17 | L: 17 R: 17 |
| PD12 | M | 71 | 12 | 7 | Right | No | 0 mg LEDD | L: 2/C+ R: 11/C+ |
3.5V 80μs 90Hz 3.6V 80μs 90Hz |
L: 2/C+ R: 10/C+ |
3V 60μs 130Hz 3V 60μs 130Hz |
18 | L: 18 R: 18 |
| PD13 | M | 72 | 21 | 7 | Right | Yes | Levodopa amantadine 1098 mg LEDD | L: 2/C+ R: 8/C+ |
2.3V 70μs 185Hz |
L: 2/C+ R: 10/C+ 2.9V 90μs 185Hz |
3V 60μs 130Hz 3V 60μs 130Hz |
26 | L: 26 R: 24 |
| Mean (±SE) | 60.1 (3.0) | 16 (2.0) | 6.9 (0.6) | 1318.7 (169.4) | 19.6 (1.2) | 19.2 (1.2) | |||||||
Tremor present at the moment of the trial.
Peaks reported here were calculated offline. Therefore, they might slightly differ with the frequencies used to filter the signal intraoperatively.
Due to a technical failure in one of the LFP channels, this patient was measured unilaterally in both hemispheres.
This patient had the right electrode implanted in the GPi. Therefore, only results from the right hand (left electrode) were included in the analysis.
This patient had the right electrode off as their standard clinical setting, as only the right hemibody required both stimulation and medication to supress clinical symptoms. However, both electrodes were tested and included in the analysis.